This is in accordance with results published from a phase 2 study of DA-EPOCH-R or R-CHOP +/− acalabrutinib for treatment naïve DLBCL by Roscheswki et al. [24], however, patients with detectable ctDNA had worse 18-months PFS of ~30% PFS compared to 60% PFS in our study. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.